WHO warns that Sudanese violence brings “huge biological risk” to lab holding samples of deadly diseases; Danaher slashes annual sales growth forecast; Ideaya Biosciences plots $150 million initial public offering.
FDA approves Biogen and Ionis’ Tofersen for rare genetic form of ALS
Bluebird Bio submits application for sickle cell therapy lovo-cel to FDA; Foghorn Therapeutics study put on partial hold after serious heart-related safety event; Florida’s plan to get cheaper prescription drugs from Canada snarled in a legal back-and-forth.
Tarsus Pharmaceuticals brings on Jeff Farrow as CFO